Navigation Links
Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Date:12/4/2007

Milestone Triggers Payment to Sangamo from JDRF

RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center Phase 2 clinical trial evaluating SB-509, a ZFP Therapeutic(TM) for the treatment of mild to moderate diabetic neuropathy (DN). The company expects to have data from this trial in the second half of 2008.

"The completion of enrollment of our first Phase 2 clinical trial represents a significant milestone for Sangamo and I am pleased that we achieved this major clinical goal as planned, before the end of 2007," commented Edward Lanphier, Sangamo's president and CEO. "We have been very encouraged by the disease-altering improvements that we observed in our preclinical studies and in the Phase 1b trial and look forward to presenting the data from this current study by the end of 2008."

This Phase 2 trial followed a positive Phase 1 study that demonstrated clinical safety of a single treatment with SB-509 as well as statistically significant improvements in Quantitative Sensory Testing (QST), clinically relevant improvements in motor and sensory nerve conduction velocities (NCV) and a trend towards improvement in Total Neuropathy Score (TNS), suggesting an alteration of disease progression in subjects with DN. The Phase 2 study was designed to confirm and expand these findings and to evaluate repeat dosing with SB-509.

The trial has been partially funded by a $3.0 million commitment from the Juvenile Diabetes Research Foundation International (JDRF) pursuant to a research agreement between Sangamo and JDRF. Com
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 27, 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... following financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over ... loss for the quarter of $240,156 compared to net income ... For the nine months ended June 30, ...
(Date:8/27/2014)... Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... H. Mackaness is scheduled to make an investor presentation ... 2:55 p.m. Eastern Time on Wednesday, September 3, in New ... the investor presentation will be available in the Investors section ... About IRIDEX IRIDEX Corporation was founded in ...
(Date:8/27/2014)... CITY, Calif. , Aug. 27, 2014  AcelRx ... pharmaceutical company focused on the development and commercialization of ... pain, today announced that senior management will be participating ... presenting at the Morgan Stanley Global Healthcare Conference.  Details ... FBR Healthcare One on One Conference Date: Wednesday September ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 2AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events 3
(Date:8/27/2014)... August 27, 2014 The Global and ... study on the current state of the Maleic Anhydride ... a basic overview of the industry, including definitions, applications ... domestic market analysis are provided with a focus on ... A comparison between the international and Chinese situation is ...
(Date:8/27/2014)... IQ Formulations , a leading manufacturer of ... of the Cystic Fibrosis Foundation. For an entire month ... led by TigerFitness.com in which 5 percent of the ... to the respected nonprofit organization. , Last year, ... Isla, a young girl fighting Cystic Fibrosis. The company ...
(Date:8/27/2014)... 27, 2014 Aspirus Wausau Hospital today ... US with Buzz™ Digital O.R. at Aspirus Wausau Hospital, ... 13 new operating rooms will be Buzz, a centralized ... integrative system supports planning, navigation, imaging and communications connectivity. ... of intuitive software and hardware all controlled from the ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
Breaking Medicine News(10 mins):Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:IQ Formulations Contributes Sizeable Donation to Cystic Fibrosis Foundation 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3
... WASHINGTON, DCThrough the identification of a gene,s impact on ... Center continue to make progress in understanding the ... repair of white matter, known as myelination. The study, ... of The Journal of Neuroscience , identified ...
... of the 5.3 million men and women seen in Department ... that use of cocaine is predictive of open-angle glaucoma, the ... that after adjustments for race and age, current and former ... Men with open-angle glaucoma also had significant exposures to amphetamines ...
... found that patients had little or no control over their ... care, but a new study shows that this has changed ... with health coverage that includes a high deductible and either ... their costs even after they initiated care. ...
... THURSDAY, Sept. 29 (HealthDay News) -- The bellowing of male ... researchers report. They found that the largest koalas produce ... males that they,re the biggest dudes in the neighborhood. ... few animals with a descended larynx, which makes the vocal ...
... their everyday lives and with support from partners can continue ... of the preliminary findings of a two-year research project funded ... married couples living with dementia make decisions on a daily ... over issues such as what to eat or wear, as ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- Cancer patients ... can have serious side effects and even mean the ... crucial that patients insist doctors use plain language ... associate professor of internal medicine at the University of ...
Cached Medicine News:Health News:Children's National researchers make breakthrough in understanding white matter development 2Health News:Children's National researchers make breakthrough in understanding white matter development 3Health News:Cocaine users have 45 percent increased risk of glaucoma 2Health News:Study finds consumers may have more control over health costs than previously thought 2Health News:Study finds consumers may have more control over health costs than previously thought 3Health News:Living with dementia and making decisions 2Health News:Cancer Patients Should Ask Doctors to Use Simple Terms 2
Instrument Cover for Vibratome....
These specialty razor blades are feather thin and very sharp. Most users have found an increased quality level in Vibratome sections with these blades....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
Medicine Products: